Key result
High baseline serum ACE2 activity (≥45.4 mU/L) predicted a higher risk of 30-day mortality (65% vs. 37%; P<0.0001) in hospitalized COVID-19 patients.
Why the study?
Angiotensin-converting enzyme 2 (ACE2) is the primary receptor for SARS-CoV-2 to enter endothelial cells, prompting investigation into whether circulating ACE2 activity predicts COVID-19 severity and mortality.
Does circulating ACE2 activity predict disease severity and 30-day mortality in hospitalized COVID-19 patients?
Cohort (n=208)
Does circulating ACE2 activity predict disease severity and 30-day mortality in hospitalized COVID-19 patients?
Absolute Event Rate: 65% vs 37%
p-value: p=<0.0001
Elevated serum ACE2 activity at hospital admission independently predicts disease severity and 30-day mortality in patients with COVID-19.
No takes yet. Share an insight, caveat, or question.
May aid prognostication in hospitalized COVID-19; hypothesis-generating and requires prospective validation before clinical use.
Fagyas et al. (2021) conducted a cohort in COVID-19 (n=208). High serum ACE2 activity (≥45.4 mU/L) vs. Low serum ACE2 activity (<45.4 mU/L) was evaluated on 30-day mortality (p=<0.0001). High baseline serum ACE2 activity (≥45.4 mU/L) predicted a higher risk of 30-day mortality (65% vs. 37%; P<0.0001) in hospitalized COVID-19 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: